Text Size
19 studies found for:    Open Studies | spectrum pharmaceuticals

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | spectrum pharmaceuticals
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
Condition: Follicular Lymphoma
Interventions: Drug: Zevalin;   Drug: Rituximab
2 Not yet recruiting Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
Condition: Non Hodgkin's Lymphoma
Interventions: Drug: Fusilev;   Drug: Folotyn
3 Recruiting Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Condition: Peripheral T-cell Lymphoma
Intervention:
4 Recruiting Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Condition: Multiple Myeloma
Intervention: Drug: High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)
5 Recruiting Maximum Tolerated Dose Study of Belinostat (PXD-101)in Combination With Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients With Stage IV Non-Small-Cell Lung Cancer (NSCLC)
Condition: Stage IV Non-small Cell Lung Cancer
Intervention: Drug: Belinostat, Carboplatin, Paclitaxel
6 Not yet recruiting Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: SPI-1620 & Docetaxel;   Drug: Docetaxel
7 Recruiting Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Condition: Neutropenia
Interventions: Drug: HM10460A (45 μg/kg);   Drug: HM10460A (135 μg/kg);   Drug: HM10460A (270 μg/kg);   Drug: Pegfilgrastim 6mg
8 Not yet recruiting Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
Condition: Advanced Cancer
Intervention: Drug: Belinostat
9 Recruiting Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: Pralatrexate Injection
10 Recruiting Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Conditions: Diffuse Large B-cell Lymphoma;   Follicle Center Lymphoma
Intervention: Drug: Zevalin (ibritumomab tiuxetan)
11 Recruiting Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Condition: Biliary Cancer
Intervention: Drug: SPI-1620 & Docetaxel
12 Not yet recruiting Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Folotyn;   Drug: Fusilev
13 Recruiting International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Ozarelix;   Drug: Goserelin
14 Recruiting Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Belinostat;   Drug: CHOP
15 Recruiting Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Conditions: Leukemia;   Lymphoma
Interventions: Drug: Rituximab;   Drug: 111In Ibritumomab;   Procedure: Planar Scintigraphy Imaging;   Drug: 90Y IbritumomabTiuxetan;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate;   Drug: G-CSF;   Procedure: Stem Cell Transplantation
16 Recruiting Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
Condition: Lymphoma, Follicular
Interventions: Drug: Bendamustine;   Drug: Rituximab;   Radiation: Y-90 ibritumomab
17 Recruiting Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Refractory Non Hodgkin Lymphoma;   Relapsed Non Hodgkin Lymphoma
Interventions: Biological: rituximab;   Biological: ibritumomab tiuxetan;   Biological: anti-thymocyte globulin;   Radiation: total nodal irradiation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
18 Recruiting Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Condition: Mantle-Cell Lymphoma
Intervention: Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan
19 Recruiting Pheno- & Genotyping POF (WHO III)
Conditions: Premature Ovarian Failure (POF);   Incipient Ovarian Failure;   Poor Response After Ovarian Hyperstimulation;   Early Menopause;   Hypergonadotropic Amenorrhea
Intervention:
To Top

† Indicates status has not been verified in more than two years